Aetna modified CPB 0240 covering antineoplaston therapy, effective September 26, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0240, which governs antineoplaston therapy coverage across neoplasm diagnoses and select neurological conditions. This coverage policy carries real financial exposure — antineoplaston claims have historically drawn heavy scrutiny, and the modification affects ICD-10 codes spanning the full neoplasm range (C00.0–D49.9) plus ALS (G12.21) and encounter codes for antineoplastic therapy. If your team bills for oncology infusions, chemotherapy encounters, or radiation therapy coordination, CPB 0240 Aetna is a policy you need in your queue before claims go out the door.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Antineoplaston Therapy — CPB 0240 |
| Policy Code | CPB 0240 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Oncology, Neurology, Infusion Therapy, Radiation Oncology |
| Key Action | Audit all antineoplaston-related claims and prior authorization workflows before submitting against the updated policy |
Aetna Antineoplaston Therapy Coverage Criteria and Medical Necessity Requirements 2025
The Aetna antineoplaston therapy coverage policy has a long and complicated history — and not in a favorable way for billing teams. Antineoplaston therapy, developed at the Burzynski Clinic, involves peptides and amino acid derivatives administered as an experimental cancer or ALS treatment. Aetna's position has consistently been that this treatment does not meet medical necessity standards for coverage.
The applicable diagnosis codes tell you the scope of this policy. It spans all neoplasms from C00.0 through D49.9 — that's the entire ICD-10 neoplasm chapter — plus G12.21 for amyotrophic lateral sclerosis. The encounter codes Z51.0 (encounter for antineoplastic radiation therapy), Z51.11, and Z51.12 (encounter for antineoplastic chemotherapy and immunotherapy) are also listed, which means the policy touches claims you might otherwise assume are clean.
The real issue here is scope creep on denials. If an antineoplaston therapy claim gets paired with a Z51.11 or Z51.12 encounter code on the same date of service, you could see a claim denial on the encounter itself — not just the therapy. Review your claim pairing logic carefully.
Prior authorization for antineoplaston therapy under this policy is, for practical purposes, irrelevant — Aetna classifies this treatment as experimental and investigational. No prior auth pathway changes that classification. If a patient is receiving antineoplaston therapy and expects Aetna reimbursement, the documentation burden falls on the provider to demonstrate that the treatment meets medical necessity criteria that Aetna has not recognized for this modality.
Aetna Antineoplaston Therapy Exclusions and Non-Covered Indications
This is where CPB 0240 gets direct. Antineoplaston therapy is classified as experimental, investigational, and unproven by Aetna. That designation applies to all indications within the policy's scope — neoplasms and ALS alike.
The experimental classification is not new. What the September 26, 2025 modification signals is that Aetna reviewed the evidence base again and did not change its position. That matters for your billing team because it closes the door on any informal assumption that updated clinical research might have shifted coverage. It has not.
For ALS specifically — G12.21 — this is a point of particular frustration for patients and providers. There is active patient advocacy around antineoplaston access for neurological conditions. But Aetna's coverage policy does not distinguish between oncology and neurology indications. The experimental designation applies across the board.
If you have patients in clinical trials receiving antineoplaston therapy, check whether the clinical trial billing rules apply. Aetna has separate policy language governing clinical trial coverage. That coverage policy may offer a path for routine costs, but it does not make antineoplaston therapy itself covered.
Coverage Indications at a Glance
| Indication | Status | Relevant ICD-10 Codes | Notes |
|---|---|---|---|
| Any neoplasm (all stages, all types) | Not Covered — Experimental | C00.0–D49.9 | Applies across the full neoplasm chapter; no exceptions documented |
| Amyotrophic lateral sclerosis (ALS) | Not Covered — Experimental | G12.21 | No coverage for neurological indications either |
| Encounter for antineoplastic radiation therapy | Not Covered when paired with antineoplaston | Z51.0 | Denial risk when billed alongside antineoplaston services |
| Encounter for antineoplastic chemotherapy/immunotherapy | Not Covered when paired with antineoplaston | Z51.11, Z51.12 | Same denial risk as Z51.0 in combined billing scenarios |
Aetna Antineoplaston Therapy Billing Guidelines and Action Items 2025
The September 26, 2025 effective date has passed. If your team hasn't already aligned your billing workflows to the updated CPB 0240, do it now. Here are the specific steps.
| # | Action Item |
|---|---|
| 1 | Audit open and pending claims that include G12.21 or any C00.0–D49.9 diagnosis paired with antineoplaston therapy billing. Pull a 90-day lookback from September 26, 2025. Any claims submitted after that date should reflect the updated policy. |
| 2 | Update your denial management queue to flag CPB 0240 as the denial reason for antineoplaston claims. When Aetna issues a claim denial citing experimental/investigational status, your team needs to route those quickly — appeals based on medical necessity arguments have a low success rate here, but clinical trial billing exceptions may apply in specific cases. |
| 3 | Check your charge capture for Z51.0, Z51.11, and Z51.12 against antineoplaston billing. These encounter codes are listed in the policy. If they appear on the same claim as antineoplaston services, you're creating a broader denial surface. Talk to your coding team about how those encounters are being documented and whether the diagnosis linkage is creating claim risk. |
| 4 | Review any active prior authorization requests tied to antineoplaston therapy. Prior authorization won't unlock coverage here, but submitting one creates a paper trail that may complicate appeals. Make sure your clinical staff understands that a prior auth approval for a related service does not constitute approval for antineoplaston therapy itself. |
| 5 | If you have patients enrolled in clinical trials receiving antineoplaston therapy, consult your compliance officer before billing. Clinical trial coverage rules are separate from CPB 0240, and the interaction between them is not always obvious. This is a situation where a billing decision can become a compliance issue. Loop in your compliance officer before September 26, 2025 encounter dates hit your AR. |
| 6 | Document all patient financial counseling conversations about antineoplaston coverage. If Aetna-insured patients are pursuing this therapy, they need to understand before treatment that reimbursement is not available under this coverage policy. Lack of documentation creates downstream liability. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Antineoplaston Therapy Under CPB 0240
The policy data for CPB 0240 does not list specific CPT or HCPCS codes. Aetna did not publish procedure codes in this bulletin's current form. The absence of CPT codes is itself a billing consideration — it means denials will be driven by the experimental/investigational designation, not a specific code-level exclusion. Any procedure code paired with antineoplaston therapy documentation can be affected.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C00.0–D49.9 | Neoplasms (full chapter range) |
| G12.21 | Amyotrophic lateral sclerosis |
| Z51.0 | Encounter for antineoplastic radiation therapy |
| Z51.11 | Encounter for antineoplastic chemotherapy and immunotherapy |
| Z51.12 | Encounter for antineoplastic chemotherapy and immunotherapy |
The range C00.0–D49.9 covers every neoplasm in ICD-10 — benign, malignant, in situ, and uncertain behavior. That's intentional on Aetna's part. It signals that no cancer type or stage makes antineoplaston therapy a covered service under this policy.
Z51.11 and Z51.12 carry the same description in the policy data. That's worth flagging to your coding team. When both appear in your charge capture, confirm they are being applied to distinct encounter types and not duplicating on a single claim.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.